Showing CypComp Card for CC02107: Ifosfamide (CypBoM Training Set)

Record Information
Version1.0
Creation Date2019-07-14 16:36:52 UTC
Last Updated2019-10-01 21:41:27 UTC
CypComp IDCC02107
Compound Information
NameIfosfamide
Structure ImageHomgksmuegbaab cqszacivsa n
InChIKeyHOMGKSMUEGBAAB-CQSZACIVSA-N
PubChem ID9588020
CypCompound Information
SetCypBoM Training Set
Bonds of Metabolism (BoMs)
CYP1A2CYP2A6CYP2B6CYP2C8CYP2C9CYP2C19CYP2D6CYP2E1CYP3A4
  • Not Available
  • <8,H;Hydroxylation;R1>
  • <8,H;Hydroxylation;R1>
  • <6,2;Cleavage;R2>
  • <6,H;Oxidation;R2>
  • <7,5;Cleavage;R3>
  • <7,H;Oxidation;R3>
  • <8,H;Hydroxylation;R1>
  • <8,H;Hydroxylation;R1>
  • <8,H;Hydroxylation;R1>
  • Not Available
  • Not Available
  • <8,H;Hydroxylation;R1>
  • <6,2;Cleavage;R2>
  • <6,H;Oxidation;R2>
  • <7,5;Cleavage;R3>
  • <7,H;Oxidation;R3>
References
  1. Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. [PubMed:10348794 ]
  2. Roy P, Tretyakov O, Wright J, Waxman DJ: Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos. 1999 Nov;27(11):1309-18. [PubMed:10534317 ]
Download FileCC02107.sdf